Skip to main content

Welcome to Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases, specifically Inflammatory Bowel Diseases (IBD), colon infections and colon diagnosis, as well as selected topically treated Skin Disorders.

Product Pipeline

The company is developing a range of pharmaceutical product projects that are mostly based on its
Multi Matrix MMX® technology.

Find out more

Therapeutic Focus

Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating inflammatory processes of the gastro-intestinal tract mainly represented by Ulcerative Colitis and Crohn’s Disease. Both diseases are clinically similar and may be described as a faulty regulation of the mucosal immune response.

The MMX technology allows the delivery of a series of API’s to the colon. The focus is thus expanded to other colon diseases that can be topically treated.

In colon cancer diagnosis endoscopists strive to identify all polyps and remove those that are potentially dangerous. CB-17-01 is a methylene blue application of the MMX tablet where the MMX technology is used to  bring the vital dye methylene blue to the colon where is stains the polyps and allows their better identification.  After their identification, the polyps need to be removed. CB-17-04, the SIC 8000, is a sub-mucosal injectable composition that allows an easier, faster and safer removal of such polyps.

Topically treated skin diseases such as acne, hirsutism and androgenetic alopecia are being targeted by the Company’s new chemical entity CB-03-01.

Business Fields

Cosmo is engaged in two distinct fields:

  • Development and commercialisation of proprietary pharmaceutical products, primarily focused on the treatment of Inflammatory Bowel Diseases, colon infections as well as colon disease diagnosis and for selected topically treated skin disorders.
  • Manufacturing of pharmaceutical products for third parties and the provision of related services.